Marie Fillon

Marie Fillon

Spoken Languages
French English
Marie Fillon
+33 (0)1 85 65 72 30

Marie Fillon is a partner in Goodwin’s Technology and Life Sciences groups. She specializes in intellectual property law and focuses mainly on transactions in life sciences, including licenses, collaborations, R&D, manufacturing, and distribution agreements. She also advises clients on intellectual property-related issues in connection with their equity financing, mergers and acquisitions, and private equity transactions as well as with their IPOs.

Marie has significant experience in litigation, in particular in relation to patents or breach or licenses or collaborations.

Prior to joining Goodwin in 2021, Marie was a national partner at Dechert and served previously as a senior associate at a leading French intellectual property law firm. Her previous experience also includes serving in the intellectual property department of a Magic Circle firm in Paris.


Marie’s experience includes advising:

Life Sciences

  •  Tribun Health, a developer of diagnostic imaging software designed to provide digital transformation of a cancer diagnosis, in the negotiation of a strategic partnership with Owkin to advance the development and global deployment of Artificial Intelligence (AI) Diagnostic and Research solutions for pathology departments and pharma companies
  • A listed clinical-stage biopharmaceutical company:
    •  in the negotiation of a licensing agreement with a Japanese company for the development and commercialization of its drug candidate in Japan and South Korea
    • in the negotiation of a licensing and collaboration agreement with a leading Chinese pharmaceutical group for the development and commercialization of its drug candidate in China
  • VistaCare Medical, a manufacturer of medical devices for the treatment of non-contact wounds, in the negotiation of a collaboration agreement with Dermatoo to advance the development of a portable medical device for wound healing
  • Mablink Bioscience, a biotechnology company that seeks to bring new and better treatment options to cancer patients with unmet need, in the IP aspects of its sale to Lilly & Co.
  • Genfit, a French late-stage biopharmaceutical company, listed on Nasdaq and Euronext, dedicated to improving the lives of patients with metabolic and chronic liver diseases, in its licensing agreement with Genoscience Pharma, a French clinical-stage biotechnology company developing novel lysomotropic therapeutics to establish a new standard of care against cancer, autoimmune and infectious diseases
  • Germitec, a healthcare company that designs, commercialize UV-C disinfection systems for hospital hygiene system, in its strategic agreements as part of its €11 million financing
  • Biomunex Pharmaceuticals, a French biopharmaceutical company, in connection with a strategic exclusive worldwide license and co-development agreement with Onward Therapeutics SA for a proprietary bispecific antibody program, as well as in its Series A funding round*
  • Robocath in its strategic agreement signed with MicroPort, a leading global developer, manufacturer and operator focusing on minimally invasive intervention products for the treatment of vascular diseases and pathological changes, to set up a China-based joint-venture company, for the commercialization of its first robotic-assisted platform to the Asian market*


  • ITEN, the French specialist in Li-ion ceramic technology, in the IP aspects of its €80 million fundraising
  • Devialet, a French High-end speaker manufacturer, in the IP aspects of its €50 million financing
  • Scottish Equity Partners in the IP aspects in connection with its investment in Braincube, a French manufacturing data software company
  • Andreessen Horowitz (a16z) in the IP aspects of its investment in the €11 million Series A of Stoïk, the first cyber-insurtech in Europe
  • Astorg Partners in the IP aspects of its investment in the $500 million financing of Ecovadis, the leading provider of globally trusted business sustainability ratings

*Denotes experience prior to joining Goodwin.




Université Paris II Panthéon-Assas

(Business Law)


Université Paris II Panthéon-Assas

(Industrial and Intellectual Property Rights)



  • Paris

Recognition & Awards

Marie is recognized for her experience by International and French preeminent, peer-reviewed publications.

  • Ranked as Up and Coming in Pharma/Life Sciences (Intellectual Property) in the last edition of the Chambers Europe guide
  • Team ranked in Tier 4 in Intellectual Property – Patents in the last edition of the Legal 500 EMEA guide
  • Recommended in Intellectual Property in the last edition of Best Lawyers France

As a successful woman professional, Marie is committed to promoting Women leadership both inside and outside of the firm. As such, she co-leads Goodwin’s Paris Women’s Initiative Committee and has been driving women-oriented mentoring sessions, client initiatives and networking opportunities.


Speaking Engagements

  •  Speaker at the Cyber Week, June 2022
  • Speaker at the EU Pharmaceutical Law Forum, May 2021
  • Speaker at the EU Pharmaceutical Law Forum, November 2020
  • Speaker at the EU Pharmaceutical Law Forum, May 2019


  • Author, “[Covid-19] Où en sont les débats sur la licence d'office de brevets pour accélérer la production de vaccins ?”, L’Usine Nouvelle, May 2021
  • Author, “Après la Covid-19, le plan d’action de l’UE pour la propriété intellectuelle”, L’Usine Nouvelle, February 2021
  • Author, “Intellectual Property cause (employment) Q&A: France”, Practical Law, October 2020
  • Author, “L’arrêt Santen et la notion de deuxième application thérapeutique en matière de certificats complémentaires de protection (CCP) : une interprétation stricte du règlement européen”, L’Usine Nouvelle, October 2020
  • Author, “Covid-19, brevets et licences d'office pour les medicaments”, L’Usine Nouvelle, May 2020
  • Author, “Essais cliniques et déchéances de marques pharmaceutiques pour défaut d'exploitation”, L’Usine Nouvelle, March 2020